{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:02:50Z","timestamp":1771434170923,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"JST SPRING","award":["JPMJSP2180"],"award-info":[{"award-number":["JPMJSP2180"]}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K18383, JP24K02333"],"award-info":[{"award-number":["JP22K18383, JP24K02333"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24ama221210h0003, JP25ck0106795h0003, JP25ama221231h0002, 25ama221242h0001"],"award-info":[{"award-number":["JP24ama221210h0003, JP25ck0106795h0003, JP25ama221231h0002, 25ama221242h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007412","name":"Nippon Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04279-7","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T22:27:14Z","timestamp":1767479234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicity"],"prefix":"10.1007","volume":"75","author":[{"given":"Masaru","family":"Yokomura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Hirohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Torigoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Asakage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"issue":"16","key":"4279_CR1","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507\u20131517. https:\/\/doi.org\/10.1056\/NEJMoa1407222","journal-title":"N Engl J Med"},{"issue":"7941","key":"4279_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05376-8","volume":"612","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici I, Nobles CL, Maji S, Frey NV, Gill SI, Loren AW, Tian L, Kulikovskaya I, June CH (2022) Author correction: decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature 612(7941):E22. https:\/\/doi.org\/10.1038\/s41586-022-05376-8","journal-title":"Nature"},{"issue":"3","key":"4279_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1158\/1535-7163.MCT-23-0310","volume":"23","author":"A Douge","year":"2024","unstructured":"Douge A, El Ghazzi N, Lemal R, Rouzaire P (2024) Adoptive T cell therapy in solid tumors: state-of-the art, current challenges, and upcoming improvements. Mol Cancer Ther 23(3):272\u2013284. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0310","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"4279_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S (2023) TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv 9(7):eadf3700. https:\/\/doi.org\/10.1126\/sciadv.adf3700","journal-title":"Sci Adv"},{"issue":"6","key":"4279_CR5","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1093\/oncolo\/oyad078","volume":"28","author":"R Yarza","year":"2023","unstructured":"Yarza R, Bover M, Herrera-Juarez M, Rey-Cardenas M, Paz-Ares L, Lopez-Martin JA, Haanen J (2023) Efficacy of T-cell receptor-based adoptive cell therapy in cutaneous melanoma: a meta-analysis. Oncologist 28(6):e406\u2013e415. https:\/\/doi.org\/10.1093\/oncolo\/oyad078","journal-title":"Oncologist"},{"issue":"3","key":"4279_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00262-020-02735-0","volume":"70","author":"J Qu","year":"2021","unstructured":"Qu J, Mei Q, Chen L, Zhou J (2021) Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. Cancer Immunol Immunother 70(3):619\u2013631. https:\/\/doi.org\/10.1007\/s00262-020-02735-0","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4279_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong DS, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, Clarke JM, Araujo D, Blumenschein GR Jr., Kebriaei P, Lin Q, Tipping AJ, Sanderson JP, Wang R, Trivedi T, Annareddy T, Bai J, Rafail S, Sun A, Butler MO (2023) Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial. Nat Med 29(1):104\u2013114. https:\/\/doi.org\/10.1038\/s41591-022-02128-z","journal-title":"Nat Med"},{"issue":"1","key":"4279_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/mt.2013.242","volume":"22","author":"WK Chia","year":"2014","unstructured":"Chia WK, Teo M, Wang WW, Lee B, Ang SF, Tai WM, Chee CL, Ng J, Kan R, Lim WT, Tan SH, Ong WS, Cheung YB, Tan EH, Connolly JE, Gottschalk S, Toh HC (2014) Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma. Mol Ther 22(1):132\u2013139. https:\/\/doi.org\/10.1038\/mt.2013.242","journal-title":"Mol Ther"},{"issue":"4","key":"4279_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","volume":"28","author":"SS Neelapu","year":"2022","unstructured":"Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC (2022) Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med 28(4):735\u2013742. https:\/\/doi.org\/10.1038\/s41591-022-01731-4","journal-title":"Nat Med"},{"issue":"6","key":"4279_CR10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.medj.2024.03.001","volume":"5","author":"J Liu","year":"2024","unstructured":"Liu J, Jiao X, Ma D, Fang Y, Gao Q (2024) CAR-T therapy and targeted treatments: emerging combination strategies in solid tumors. Med 5(6):530\u2013549. https:\/\/doi.org\/10.1016\/j.medj.2024.03.001","journal-title":"Med"},{"issue":"1","key":"4279_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40164-024-00536-0","volume":"13","author":"D Zhou","year":"2024","unstructured":"Zhou D, Zhu X, Xiao Y (2024) CAR-T cell combination therapies in hematologic malignancies. Exp Hematol Oncol 13(1):69. https:\/\/doi.org\/10.1186\/s40164-024-00536-0","journal-title":"Exp Hematol Oncol"},{"key":"4279_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.omtm.2020.09.011","volume":"19","author":"T Maeda","year":"2020","unstructured":"Maeda T, Nagano S, Kashima S, Terada K, Agata Y, Ichise H, Ohtaka M, Nakanishi M, Fujiki F, Sugiyama H, Kitawaki T, Kadowaki N, Takaori-Kondo A, Masuda K, Kawamoto H (2020) Regeneration of tumor-antigen-specific cytotoxic T lymphocytes from iPSCs transduced with exogenous TCR genes. Mol Ther Methods Clin Dev 19:250\u2013260. https:\/\/doi.org\/10.1016\/j.omtm.2020.09.011","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"23","key":"4279_CR13","doi-asserted-by":"publisher","first-page":"6839","DOI":"10.1158\/0008-5472.CAN-16-1149","volume":"76","author":"T Maeda","year":"2016","unstructured":"Maeda T, Nagano S, Ichise H, Kataoka K, Yamada D, Ogawa S, Koseki H, Kitawaki T, Kadowaki N, Takaori-Kondo A, Masuda K, Kawamoto H (2016) Regeneration of CD8alphabeta T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity. Cancer Res 76(23):6839\u20136850. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1149","journal-title":"Cancer Res"},{"issue":"4","key":"4279_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.100998","volume":"23","author":"S Kashima","year":"2020","unstructured":"Kashima S, Maeda T, Masuda K, Nagano S, Inoue T, Takeda M, Kono Y, Kobayashi T, Saito S, Higuchi T, Ichise H, Kobayashi Y, Iwaisako K, Terada K, Agata Y, Numakura K, Saito M, Narita S, Yasukawa M, Kawamoto H (2020) Cytotoxic T lymphocytes regenerated from iPS cells have therapeutic efficacy in a patient-derived xenograft solid tumor model. iScience 23(4):100998. https:\/\/doi.org\/10.1016\/j.isci.2020.100998","journal-title":"iScience"},{"issue":"12","key":"4279_CR15","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1158\/0008-5472.CAN-20-3436","volume":"81","author":"HF Tu","year":"2021","unstructured":"Tu HF, Ko CJ, Lee CT, Lee CF, Lan SW, Lin HH, Lin HY, Ku CC, Lee DY, Chen IC, Chuang YH, Del Cano-Ochoa F, Ramon-Maiques S, Ho CC, Lee MS, Chang GD (2021) Afatinib exerts immunomodulatory effects by targeting the pyrimidine biosynthesis enzyme CAD. Cancer Res 81(12):3270\u20133282. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3436","journal-title":"Cancer Res"},{"issue":"4","key":"4279_CR16","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1002\/cam4.5310","volume":"12","author":"T Sasaya","year":"2023","unstructured":"Sasaya T, Kubo T, Murata K, Mizue Y, Sasaki K, Yanagawa J, Imagawa M, Kato H, Tsukahara T, Kanaseki T, Tamura Y, Miyazaki A, Hirohashi Y, Torigoe T (2023) Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma. Cancer Med 12(4):4605\u20134615. https:\/\/doi.org\/10.1002\/cam4.5310","journal-title":"Cancer Med"},{"issue":"4","key":"4279_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1293214","volume":"6","author":"V Kochin","year":"2017","unstructured":"Kochin V, Kanaseki T, Tokita S, Miyamoto S, Shionoya Y, Kikuchi Y, Morooka D, Hirohashi Y, Tsukahara T, Watanabe K, Toji S, Kokai Y, Sato N, Torigoe T (2017) HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses. Oncoimmunology 6(4):e1293214. https:\/\/doi.org\/10.1080\/2162402X.2017.1293214","journal-title":"Oncoimmunology"},{"key":"4279_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173688","author":"N Kondo","year":"2023","unstructured":"Kondo N, Utsumi T, Shimizu Y, Takemoto A, Oh-hara T, Uchibori K, Subat-Motoshi S, Ninomiya H, Takeuchi K, Nishio M, Miyazaki Y, Katayama R (2023) MIG6 loss confers resistance to ALK\/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.173688","journal-title":"JCI Insight"},{"issue":"7","key":"4279_CR19","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O\u2019Shea JJ (2011) Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186(7):4234\u20134243. https:\/\/doi.org\/10.4049\/jimmunol.1003668","journal-title":"J Immunol"},{"key":"4279_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","author":"K Mestermann","year":"2019","unstructured":"Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, Mades A, Sadelain M, Einsele H, Hudecek M (2019) The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aau5907","journal-title":"Sci Transl Med"},{"issue":"5","key":"4279_CR21","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.immuni.2023.03.006","volume":"56","author":"K Cui","year":"2023","unstructured":"Cui K, Chen Z, Cao Y, Liu S, Ren G, Hu G, Fang D, Wei D, Liu C, Zhu J, Wu C, Zhao K (2023) Restraint of IFN-gamma expression through a distal silencer CNS-28 for tissue homeostasis. Immunity 56(5):944-958 e946. https:\/\/doi.org\/10.1016\/j.immuni.2023.03.006","journal-title":"Immunity"},{"issue":"9","key":"4279_CR22","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1007\/s00262-023-03473-9","volume":"72","author":"M Haraguchi","year":"2023","unstructured":"Haraguchi M, Kiyotani K, Tate T, Sakata S, Sagawa R, Takagi S, Nagayama S, Takeuchi K, Takahashi K, Katayama R (2023) Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancer. Cancer Immunol Immunother 72(9):2971\u20132989. https:\/\/doi.org\/10.1007\/s00262-023-03473-9","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"4279_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41568-020-00322-0","volume":"21","author":"S Kumagai","year":"2021","unstructured":"Kumagai S, Koyama S, Nishikawa H (2021) Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer 21(3):181\u2013197. https:\/\/doi.org\/10.1038\/s41568-020-00322-0","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"4279_CR24","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1158\/1078-0432.CCR-10-3283","volume":"17","author":"BP Pollack","year":"2011","unstructured":"Pollack BP, Sapkota B, Cartee TV (2011) Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res 17(13):4400\u20134413. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-3283","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4279_CR25","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","volume":"3","author":"EA Akbay","year":"2013","unstructured":"Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Wong KK (2013) Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 3(12):1355\u20131363. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0310","journal-title":"Cancer Discov"},{"issue":"1","key":"4279_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ccell.2023.12.002","volume":"42","author":"G Mucciolo","year":"2024","unstructured":"Mucciolo G, Araos Henriquez J, Jihad M, Pinto Teles S, Manansala JS, Li W, Ashworth S, Lloyd EG, Cheng PSW, Luo W, Anand A, Sawle A, Piskorz A, Biffi G (2024) EGFR-activated myofibroblasts promote metastasis of pancreatic cancer. Cancer Cell 42(1):101-118 e111. https:\/\/doi.org\/10.1016\/j.ccell.2023.12.002","journal-title":"Cancer Cell"},{"issue":"12","key":"4279_CR27","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1158\/2326-6066.CIR-18-0193","volume":"6","author":"PH Lizotte","year":"2018","unstructured":"Lizotte PH, Hong RL, Luster TA, Cavanaugh ME, Taus LJ, Wang S, Dhaneshwar A, Mayman N, Yang A, Kulkarni M, Badalucco L, Fitzpatrick E, Kao HF, Kuraguchi M, Bittinger M, Kirschmeier PT, Gray NS, Barbie DA, Janne PA (2018) A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing. Cancer Immunol Res 6(12):1511\u20131523. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0193","journal-title":"Cancer Immunol Res"},{"key":"4279_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aav3937","author":"E Sugiyama","year":"2020","unstructured":"Sugiyama E, Togashi Y, Takeuchi Y, Shinya S, Tada Y, Kataoka K, Tane K, Sato E, Ishii G, Goto K, Shintani Y, Okumura M, Tsuboi M, Nishikawa H (2020) Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. Sci Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aav3937","journal-title":"Sci Immunol"},{"issue":"2","key":"4279_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111736","volume":"28","author":"S Kim","year":"2025","unstructured":"Kim S, Koh J, Kim TM, Oh S, Kim S, Youk J, Kim M, Keam B, Jeon YK, Kim DW, Heo DS (2025) Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. iScience 28(2):111736. https:\/\/doi.org\/10.1016\/j.isci.2024.111736","journal-title":"iScience"},{"issue":"2","key":"4279_CR30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.taap.2010.12.011","volume":"251","author":"Q Luo","year":"2011","unstructured":"Luo Q, Gu Y, Zheng W, Wu X, Gong F, Gu L, Sun Y, Xu Q (2011) Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf\/ERK cascade and Akt signaling pathway. Toxicol Appl Pharmacol 251(2):130\u2013136. https:\/\/doi.org\/10.1016\/j.taap.2010.12.011","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"4279_CR31","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jtho.2018.11.028","volume":"14","author":"JC Yang","year":"2019","unstructured":"Yang JC, Gadgeel SM, Sequist LV, Wu CL, Papadimitrakopoulou VA, Su WC, Fiore J, Saraf S, Raftopoulos H, Patnaik A (2019) Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation. J Thorac Oncol 14(3):553\u2013559. https:\/\/doi.org\/10.1016\/j.jtho.2018.11.028","journal-title":"J Thorac Oncol"},{"issue":"5","key":"4279_CR32","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jtho.2019.02.001","volume":"14","author":"JC Yang","year":"2019","unstructured":"Yang JC, Shepherd FA, Kim DW, Lee GW, Lee JS, Chang GC, Lee SS, Wei YF, Lee YG, Laus G, Collins B, Pisetzky F, Horn L (2019) Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report. J Thorac Oncol 14(5):933\u2013939. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.001","journal-title":"J Thorac Oncol"},{"issue":"9","key":"4279_CR33","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1158\/2326-6066.CIR-21-0751","volume":"10","author":"K Nishii","year":"2022","unstructured":"Nishii K, Ohashi K, Tomida S, Nakasuka T, Hirabae A, Okawa S, Nishimura J, Higo H, Watanabe H, Kano H, Ando C, Makimoto G, Ninomiya K, Kato Y, Kubo T, Ichihara E, Hotta K, Tabata M, Toyooka S, Kiura K (2022) CD8+ T-cell responses are boosted by dual PD-1\/VEGFR2 blockade after EGFR inhibition in Egfr-mutant lung cancer. Cancer Immunol Res 10(9):1111\u20131126. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0751","journal-title":"Cancer Immunol Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04279-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04279-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04279-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:06:18Z","timestamp":1771430778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04279-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4279"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04279-7","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ryohei Katayama received research grants from Chugai, Nipon-Kayaku, TOPPAN, UBE, BML, EIKEN Chemical outside the submitted work. Other authors have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients and healthy donors\u00a0provided informed consent for the genetic and cell biological analyses, which were performed in accordance with protocol approved by the Institutional Review Boards of the JFCR\u00a0and the Kyoto University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"33"}}